HOME >> BIOLOGY >> NEWS
Costly tests unnecessary for some miscarriages, University of Pittsburgh geneticist says

HOT SPRINGS, Va., Jan. 27 Current standard practice in cases of repeated pregnancy loss frequently involves a lengthy series of diagnostic tests that often still do not pinpoint a cause yet amass thousands of dollars in unnecessary costs, according to a geneticist at the University of Pittsburgh School of Medicine.

With a minor adjustment concerning those patients who are recommended for an advanced work-up, patients, health care facilities and insurers could save millions of dollars each year, while still giving many couples an answer for their losses, said W. Allen Hogge, M.D., professor of obstetrics, gynecology and reproductive sciences and associate professor of human genetics at the University of Pittsburgh School of Medicine.

Dr. Hogge, who also is a clinical investigator at Magee-Womens Research Institute and medical director of genetics at Magee-Womens Hospital of the University of Pittsburgh Medical Center, will give a presentation on his findings today at the 2003 annual meeting of the South Atlantic Association of Obstetricians and Gynecologists. Results of the study also will be published in an upcoming issue of the American Journal of Obstetrics and Gynecology.

"Recurrent miscarriage is defined clinically as three consecutive pregnancy losses," said Dr. Hogge. "But even an extensive work-up will fail to find a recognizable cause in up to half of these cases."

Dr. Hogge and his colleagues analyzed the results of karyotyping tests to determine the chromosomal characteristics of cells on 517 tissue samples from miscarriages gathered over nearly five years at Magee-Womens Hospital. Overall, nearly 56 percent were found to have chromosomal abnormalities, with even higher rates of abnormalities when adjusted for maternal age. More than 82 percent of miscarriages were found to be chromosomally abnormal in women age 35 or over.

"Because 50 percent to 70 percent of miscarriages can be attributed to chromosomal abnormalit
'"/>

Contact: Michele Baum
412-647-3555
University of Pittsburgh Medical Center
27-Jan-2003


Page: 1 2

Related biology news :

1. Carnegie Mellon researcher tests tools for protecting Anacostia River ecosystem from PCBs
2. DNA tests point to extinction of 2 distinctive arctic bird populations
3. FSU scientists develop new tests to detect nut allergens in processed food
4. Only 21 states offer newborn screening tests recommended by March of Dimes
5. First time in the U.S.: Saint Louis University tests third-generation vaccine against smallpox
6. Uncertainty in clinical tests raises health care costs
7. Research to create lung-cancer blood tests receives $3.4M in Pennsylvania tobacco settlement funds
8. Current smoke alarms pass life-saving tests
9. Why results from genetic tests should be available to medical insurance companies
10. AGI announces the winners of Earth Science Week 2003 contests
11. Lab tests can reveal how patients respond to Gleevec

Post Your Comments:
(Date:5/21/2013)... at Chicago College of Medicine will study gender differences in ... energy source -- and how changes in fat metabolism play ... 4-year grant from the National Heart, Lung and Blood Institute. ... for energy. These changes may play a major role in ... and women, says E. Douglas Lewandowski, director of the UIC ...
(Date:5/21/2013)... charted the path of insulin action in cells in ... blueprint for understanding what goes wrong in diabetes. ... Professor David James from Sydney,s Garvan Institute of Medical ... of the prestigious journal Cell Metabolism . , ... very important role in the body because it helps ...
(Date:5/20/2013)... is known about the effect of physical education (PE) ... University finds that increasing the amount of time that ... of obesity. , The study represents some of the ... youth obesity, and is forthcoming in the Journal ... of the study can be viewed at: http://www.sciencedirect.com/science/article/pii/S0167629613000556 ...
Breaking Biology News(10 mins):Do men's and women's hearts burn fuel differently? 2Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3Gym class reduces probability of obesity, study finds for first time 2
(Date:5/21/2013)... May 21, 2013 Alpha Source, ... , will be exhibiting for the 13th consecutive ... Medical Instrumentation (AAMI) 2013 Conference and Expo. The ... distribute, and manufacture healthcare technologies. This year’s event ... Beach, California. , The three-day event draws ...
(Date:5/21/2013)... Raleigh, NC (PRWEB) May 21, 2013 ... and financial services company for clinical trials, announced ... Aggregate Spend Solutions, LLC. Clinverse’s ClinPay® FLS ... automated investigator payment process. SpendMD ™, ... only complete solution for tracking and reporting transfer ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 As ... a strong push within the industry to deliver ... Manufacturing Organizations and pharma companies often means turning ... , Microtablets, developed in collaboration with Sensidose AB ... outsourcing can bring products to market sooner. The ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. ... study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal ... expressing the HER2 oncoprotein," will be presented at ... of Clinical Oncology during the Developmental Therapeutics - ... at 4:15 – 4:30 PM.  The presentation will ...
Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: